索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]刘晶,郭晨浩,王小涛,等.减重代谢手术治疗肥胖症合并高血压的机制[J].国际心血管病杂志,2022,05:285-288.
点击复制

减重代谢手术治疗肥胖症合并高血压的机制(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年05期
页码:
285-288
栏目:
综述
出版日期:
2022-10-01

文章信息/Info

Title:
-
作者:
刘晶; 郭晨浩; 王小涛; 侯以森; 韩建立
030032 太原，山西医科大学第三医院普通外科
Author(s):
-
关键词:
减重手术; 高血压; 肥胖症
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.05.009
文献标识码:
-
摘要:
减重代谢手术能使肥胖合并高血压患者血压下降，其机制可能包括减重术后脂 肪组织减少、脂联素释放增加、瘦素水平降低、压力感受性反射改善、交感神经系统抑制、 肾脏钠排泄改善、胃肠道激素和肠道菌群结构和功能改变等。
Abstract:
-

参考文献/References

[1] 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[2] Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension[J]. JAMA, 2020, 324(12):1190-1200.
[3] 陈祚, 李苏宁, 王馨, 等. 我国中年人群高血压、超重和肥 胖的发病率及其与心血管事件的关系[J]. 中华高血压杂志, 2020, 28(11):1100.
[4] Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes[J]. N Engl J Med, 2012, 366(17):1567-1576.
[5] Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension)[J]. Circulation, 2018, 137:1132-1142.
[6] 中国超重/肥胖医学营养治疗专家共识编写委员会. 中国超 重/肥胖医学营养治疗专家共识(2016年版)[J]. 中华糖尿病 杂志, 2016, 8(9):525-540.
[7] Schwandt P, Scholze JE, Bertsch T, et al. Blood pressure percentiles in 22051 German children and adolescents: the PEP family heart study[J]. Am J Hypertens, 2015, 28(5):672- 679.
[8] Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia[J]. Obes Res, 2000, 8(9):605-619.
[9] Nguyen Thang, Lau David CW. The obesity epidemic and its impact on hypertension[J]. Can J Cardiol, 2012, 28(3):326-33.
[10] Samson R, Milligan G, Lewine E, et al. Effect of sleeve gastrectomy on hypertension[J]. J Am Soc Hypertens, 2018, 12(11):e19-e25.
[11] Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med, 2012, 366(17):1577-1585.
[12] Stenberg E, Cao Y, Marsk R, et al. Association between metabolic surgery and cardiovascular outcome in patients with hypertension: a nationwide matched cohort study[J]. PLoS Med, 2020, 17(9):e1003307.
[13] Cabandugama PK, Gardner MJ, Sowers JR. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome[J]. Med Clin North Am, 2017, 101(1):129-137.
[14] Grassi G, Pisano A, Bolignano D, et al. Sympathetic nerve traffic activation in essential hypertension and its correlates: systematic reviews and meta-analyses[J]. Hypertension, 2018, 72(2):483-449.
[15] Seravalle G, Colombo M, Perego P, et al. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients[J]. Hypertension, 2014, 64(2):431-437.
[16] Nguyen T, Lau DC. The obesity epidemic and its impact on hypertension [J]. Can J Cardiol, 2012, 28(3):326-333.
[17] Lee JJ, Pedley A, Hoffmann U, et al. Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: the Framingham heart study[J]. Am J Med, 2018, 131(6):684-692.
[18] Lehmann S, Linder N, Retschlag U, et al. MRI assessment of changes in adipose tissue parameters after bariatric surgery[J]. PLoS One, 2018, 13(11):e0206735.
[19] Hui SCN, Wong SKH, Ai Q, et al. Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI[J]. Eur Radiol, 2019, 29(2):849-856.
[20] Conte MS, Desai TA, Wu B,et al. Pro-resolving lipid mediators in vascular disease[J]. Clin Invest, 2018, 128(9):3727-3735.
[21] Ruan CC, Gao PJ. Role of complement-related inflammation and vascular dysfunction in hypertension[J]. Hypertension, 2019, 73(5):965-971.
[22] Hagman DK, Larson I, Kuzma JN, et al. The short-term and long-term effects of bariatric/metabolic surgery on subcutaneous adipose tissue inflammation in humans[J]. Metabolism, 2017, 70:12-22.
[23] Owen JG, Yazdi F, Reisin E. Bariatric surgery and hypertension[J]. Am J Hypertens, 2017, 31(1):11-17.
[24] Kawarazaki W, Fujita T. The role of aldosterone in obesityrelated hypertension[J]. Am J Hypertens, 2016, 29(4):415-423.
[25] Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis[J]. Diabetes Obes Metab, 2017, 19(4):524-536.
[26] Pedersen JS, Borup C, Damgaard M, et al. Early 24-hour blood pressure response to Roux-en-Y gastric bypass in obese patients[J]. Scand J Clin Lab Invest, 2017, 77(1):53-59.
[27] Ricci C, Gaeta M, Rausa E, et al. Long-term effects of bariatric surgery on type Ⅱ diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year followup[ J]. Obes Surg, 2015, 25(3):397-405.
[28] Avery EG, Bartolomaeus H, Maifeld A, et al. The gut microbiome in hypertension: recent advances and future perspectives[J]. Circ Res, 2021, 128(7):934-950.
[29] Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease [J]. Nature, 2017, 551(7682):585-589.
[30] Bartolomaeus H, Balogh A, Yakoub M, et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage[J]. Circulation, 2019, 139(11):1407-1421.

备注/Memo

备注/Memo:
基金项目：“136” 兴医工程（2019XY003）；山西省科技厅 （201703D321011）
通信作者：韩建立， E-mail：1292225922@qq.com
更新日期/Last Update: 2022-10-01